Evidence suggests that patients with irritable bowel syndrome (IBS) are more vigilant to pain-associated stimuli. The aims of this study were to compare women with IBS (n ¼ 20) to healthy control (HC, n ¼ 20) women on pain sensitivity, conditioned pain modulation (CPM) efficiency, and salivary cortisol levels before and after the CPM test and to examine the relationship of CPM efficiency with gastrointestinal pain, somatic pain, psychological distress symptoms, and salivary cortisol levels in each group. Women, aged 20-42 years, gave consent, completed questionnaires, and kept a symptom diary for 2 weeks. CPM efficiency was tested with a heat test stimulus and cold water condition stimulus in a laboratory between 8 and 10 a.m. on a follicular phase day. Salivary cortisol samples were collected just before and after the experimental testing. Compared to the HC group, women with IBS reported more days with gastrointestinal and somatic pain/discomfort, psychological distress, fatigue, and feeling stressed. During the CPM baseline testing, women with IBS reported greater pain sensitivity compared to the HC group. There was no significant group difference in salivary cortisol levels nor in CPM efficiency, though a post-hoc analysis showed a higher prevalence of impaired CPM efficiency among IBS subjects with more severe lower-GI symptoms. In the IBS group, reduced CPM efficiency was associated with daily abdominal pain/discomfort and psychological distress. Overall, women with IBS exhibited an increased sensitivity to thermal stimuli. Impaired CPM was present in a subset of women with IBS.
Functional gastrointestinal (GI) disorders such as irritable bowel syndrome (IBS) are among the most common and costly health care problems in the United States (Faresjo et al., 2007; Nyrop et al., 2007; Sandler, 1990; Spiegel, Strickland, Naliboff, Mayer, & Chang, 2008) . In terms of direct and indirect cost of treating a GI disease or disorder, IBS ranks second only to gastroesophageal reflux disorders. In addition, increased severity and frequency of IBS symptom are linked to poorer quality of life (Bond et al., 2009; Spiegel et al., 2008) .
IBS is typified by the presence of abdominal pain or discomfort associated with bowel pattern changes and/or relieved by bowel movement, with patients usually suffering from diarrhea and/or constipation. In the United States, more women than men seek health care services for IBS symptoms (Lovell & Ford, 2012) . Investigators have identified a number of mechanisms as potential initiators, symptom triggers, or exacerbating factors contributing to the etiology and pathophysiology of IBS. These include peripheral mechanisms such as increased small bowel and colonic permeability changes in the colonic microbiome (Camilleri, 2012) and central mechanisms including alterations in central processing, as seen in brain imaging studies (i.e., greater activation in the prefrontal regions, anterior-and midcingulate cortex in patients with IBS compared to healthy controls (HCs; Elsenbruch, 2011; Hubbard et al., 2011; Naliboff et al., 2006; Tillisch, Mayer, & Labus, 2011) . The heightened visceral sensitivity to intestinal stimulation in individuals with IBS report may be the result of both peripheral and central mechanisms (Keszthelyi et al., 2012; Piche, Bouin, Arsenault, Poitras, & Rainville, 2011) .
As defined by the Rome III criteria, abdominal pain/discomfort is a key feature of IBS regardless of the bowel pattern disturbance. Visceral hypersensitivity, defined as an experience of pain/discomfort within the viscera that is more intense than normal, can be assessed by increasing distensions in the rectal or sigmoid area. With this paradigm, approximately 40-60% of IBS patients demonstrate significantly lower pain tolerance than a healthy comparison group (Lovell & Ford, 2012) . Another way of examining pain processing is by activating the diffuse noxious inhibitory control (DNIC) system. The DNIC system involves the spinal-medullary-spinal pathway and includes both afferent and efferent limbs. It acts as a type of filter that determines the amount of focus given to a particular stimulus within the background of normal somesthetic and visceral input (van Wijk & Veldhuijzen, 2010) . Yarnitsky and colleagues (Yarnitsky, 2010; Yarnitsky et al., 2010) recently recommended that the term conditioned pain modulation (CPM) be used in place of DNIC when referring to the observed phenomenon that pain perception is reduced by a second, conditioning pain, as determined by an experimental procedure. We follow that recommendation in this report. CPM efficiency is measured by how much a person's perception of a painful stimulus (test stimulus, e.g., warm temperature on right arm) is reduced after a second painful stimulus is applied (conditioning stimulus, e.g., left arm emerged in cold temperature bath; Heymen et al., 2010; van Wijk & Veldhuijzen, 2010) . This approach is used to determine whether deficits in the endogenous analgesic mechanism could portend greater overall sensory (cutaneous, musculoskeletal, visceral) sensitivity in patients with chronic pain conditions such as IBS (Rezaii, Hirschberg, Carlstrom, & Ernberg, 2012) . Research has revealed both gender and ethnic differences in CPM efficiency, with men showing greater CPM efficiency than women (Heymen et al., 2010) and non-Hispanic Whites showing significantly higher CPM efficiency than African Americans (Campbell et al., 2008) . In addition, menstrual cycle phase may influence CPM efficiency in healthy women (Tousignant-Laflamme & Marchand, 2009 ). For example, researchers observed greater CPM efficiency in the ovulatory phase as compared to the luteal and menstrual phases in two studies (Rezaii et al., 2012; Tousignant-Laflamme & Marchand, 2009 ). However, Bartley and Rhudy (2012) failed to show differences in CPM efficiency when they studied women in the follicular versus luteal phases.
Three studies have shown that patients with IBS demonstrate differences in CPM efficiency when compared to HCs (Heymen et al., 2010; King et al., 2009; Piche et al., 2011) . Studies of patients with other chronic pain-related conditions have shown that CPM efficiency is influenced by stress perception or the introduction of stress in a laboratory setting as well as psychological variables including anxiety and depression (Johannesson, de Boussard, Brodda Jansen, & Bohm-Starke, 2007; Normand et al., 2011) and the presence of other pain-related conditions (Arendt-Nielsen, Sluka, & Nie, 2008; Williams & Clauw, 2009 ). As a group, patients with IBS report higher levels of anxiety, depression (Goncalves de Medeiros et al., 2012; Jones, Koloski, Boyce, & Talley, 2011; Orr, Crowell, Lin, Harnish, & Chen, 1997) and stress, and more comorbid conditions (Gulewitsch, Enck, Hautzinger, & Schlarb, 2011) than healthy individuals, suggesting that CPM efficiency may be reduced in these patients. In addition, several studies found that IBS patients have dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis as evidenced by either hyper-or hyposecretion of cortisol or dysregulation between adrenocorticotropic hormone and cortisol levels (Chang et al., 2009; Heitkemper et al., 2012) . However, the relationship between HPA markers and CPM efficiency remains unexplored in patients with IBS.
Thus, the aims of the present study were to compare women with IBS to HCs on pain sensitivity, CPM efficiency, and salivary cortisol levels before and after the CPM test and to examine the relationship of CPM efficiency with GI pain, somatic pain, psychological distress symptoms, and salivary cortisol levels in each group. We hypothesized that women in the IBS group would have increased pain sensitivity and poorer CPM efficiency compared to those in the HC group.
Materials and Methods

Design and Participants
In this cross-sectional study, we recruited women (aged 18-45 years) with IBS and healthy women through the university research studies volunteers' website and flyers posted in the community. We screened women for eligibility by telephone and during the initial laboratory visit where they gave written consent before being oriented to the study protocol. To be included in the IBS group, participants had to have received a diagnosis of IBS from a health care provider (e.g., internist or gastroenterologist) at least 6 months prior to study entry. Over the preceding 3 months they had to have experienced abdominal discomfort or pain more than 25% of the time that met two of the three following descriptions: (1) relieved with defecation; (2) onset associated with a change in frequency of stool; or (3) onset associated with a change in form (appearance) of stool. Participants were classified as IBS-constipation (IBS-C) if they had greater than or equal to 25% of stools that were hard and lumpy and less than 25% loose (mushy) or watery. Criteria for IBS-diarrhea (IBS-D) were greater than or equal to 25% of stools loose and watery and less than 25% hard or lumpy. The IBS-mixed group (IBS-M) had greater than or equal to 25% of stools that met the criteria for hard and lumpy and at least 25% that met the criteria for loose and watery. We confirmed that participants met the Rome III criteria for IBS by administering the Rome III Diagnostic Questionnaire for Functional GI Disorders (Drossman et al., 2006) . Women in the HC group should not have a functional GI disorder or serious health problems. Women were excluded from either group if they (1) had a history of an organic GI disease, cardiac arrhythmia, or renal or gynecological pathology;
(2) were currently taking certain medications, that is, prokinetic drugs, laxatives (but not fiber supplements), antidiarrheals or antispasmodics for GI symptoms; (3) were currently taking other medications daily that would alter cortisol levels (e.g., phenytoin or synthetic glucocorticoids); (4) had a body mass index (BMI) > 35 kg/m 2 ; and (5) had moderate-severe comorbid pain or psychiatric conditions. We balanced the enrollment in the HC group by the age, race, and education of the women in the IBS group. The university institutional review board approved the study prior to recruitment and renewed the approval annually. We screened a total of 140 women; 3 women in the control group withdrew after the initial visit (too busy or time conflict) and 2 others were withdrawn at the initial visit when an exclusion criterion was identified.
Procedures
At the time of enrollment, the women signed informed consent and completed validated data collection tools (i.e., pain-impact, Patient-Reported Outcomes Measurement Information System [PROMIS 1 ] measures, Rome III Diagnostic Questionnaire for the Adult Functional GI Disorders, and Brief Symptom Inventory (BSI)). Women started a daily diary at the onset of their next menses and were asked to make entries each evening for approximately 14 days.
We scheduled women for the CPM testing in the laboratory following the start of menses (median ¼ 6 days after start of menses; range ¼ 4-12 days). Women were asked to maintain a clear liquid diet beginning 12 hr before their test visit and to refrain from drinking liquids for at least 1 1= 2 hr prior to the testing procedure. The CPM test took place between 08:00 and 10:00 a.m. and lasted approximately 30 min. Immediately before and immediately following the CPM test, we obtained salivary samples for cortisol measurement by having the participant passively drool through a straw into a 15-ml plastic centrifuge tube. We assured participants that the testing would be terminated at any time if they wanted to stop the procedure.
CPM Procedure
The CPM testing procedure included four phases as described subsequently. The Pain and Sensory Evaluation System (Pathway model ATS, Israel) was used to generate a noxious heat test stimulus. A 12 C water bath was used as the noxious conditioning stimulus. A trained research nurse performed the CPM testing in our psychological testing laboratory using a script to guide participants through the procedure to ensure consistency.
Familiarization phase. The familiarization phase introduced the participant to the procedure. The baseline temperature for the thermode was 32 C with increasing or decreasing (back to baseline) temperature rates of 8 C/s. The first step was to place the thermode (30 Â 30 mm 2 ) on the volar surface of the dominant arm, secured with a Velcro strap. Next the temperature of the thermode was increased to 43 C. After 6 s, the participant was told to verbally rate pain intensity on a visual numerical pain scale ranging from 0 (no pain) to 10 (worst pain imaginable). The temperature was returned to baseline for 2 s and then the procedure was repeated at 44 C. The thermode was removed for a 5-min break.
Pain sensitivity and pain-6 temperature determination phase. The second step was to determine a temperature at which the participant consistently rated pain as a 6 on the 0-10 scale (the pain-6 temperature). A series of three temperatures (45, 46, and 47 C) were administered through the thermode in random order for 7 s each with 2-s interstimuli intervals at 32 C. The participant rated pain intensity at each temperature. If the participant rated a temperature as a 6, that temperature was identified as the pain-6 temperature. If they did not, the temperatures were either increased or decreased by 1 C and the determination sequence repeated up to 3 times to identify the pain-6 temperature. In order to protect the participants from severe pain, two constraints were imposed: (1) the maximum temperature used was 48 C and (2) if at any point a participant gave a pain rating of 8 or higher, she was not tested at a temperature higher than that. At the end of this procedure, the pain-6 temperature was confirmed by activating the thermode once at that temperature for 7 s and having the woman rate her level of pain. For a few participants, a temperature rated at 5 or 7 was accepted as a substitute because they did not rate any of the temperatures as a pain-6 temperature. The pain-6 temperature, or substitute, was used as the test stimulus in the next steps. In addition, the pain ratings at different temperatures were used for analyses of pain sensitivity. At the end of this phase, the participant relaxed for 5 min with the thermode removed.
Unconditioned test stimulus. During the third step, the unconditioned test stimulus, the thermode was set at the pain-6 temperature for 30 s. The participant rated her pain from the test stimulus at 10, 20, and 30 s. The participant then relaxed for 5 min with the thermode removed.
Conditioning stimulus. In the final step, the conditioning stimulus, the participant placed her nondominant hand in a cold water bath maintained at 12 C. The nurse instructed her to keep her hand in up to the wrist with fingers apart for 1 min. For the first 30 s, the participant rated her pain from the conditioning stimulus at 10, 20, and 30 s. During the next 30 s, the pain-6 temperature was applied via the thermode on her dominant arm and she rated her pain from this test stimulus at 40, 50, and 60 s.
CPM efficiency score. The CPM efficiency score was calculated as the average of the three pain ratings for the unconditioned test stimulus minus the average of the three pain ratings for the test stimulus when the conditioning stimulus was present.
Higher positive values indicate a greater CPM efficiency.
Measures IBS characteristics. We used the Rome III Diagnostic Questionnaire for the Adult Functional GI Disorders (Drossman et al., 2006) to collect the duration of IBS symptoms since onset (''When did your IBS symptoms first start?'') and severity of pain symptoms (''Usually, how severe was the pain or discomfort in your abdomen?'') rated from 1 (very mild) to 4 (very severe).
Pain behavior. We measured pain behavior with the Pain Behavior-Short Form from the PROMIS, which asks about common pain behaviors that can be observed (thrashing), behaviors associated with pain severity (grimace, move extremely slowly, isolate myself, and irritable), verbal reports of pain rated from 1 (not at all) to 5 (very much), and one question on social activity rated from 1 (never) to 5 (always) over the past 7 days. Content validity for the PROMIS was tested with qualitative and quantitative approaches, and researchers reported good reliability (Cella et al., 2010; Magasi et al., 2012) . Internal consistency for this study was a ¼ .89. The summary score is the mean of all items, with higher scores reflecting more pain behavior.
Pain impact. We measured the impact of pain using the Pain Impact-Short Form (PROMIS), which asks about the consequences of pain on five aspects of one's life, including social, cognitive, emotional, physical, and recreational activities. Pain over the past 7 days is rated from 1 (not at all) to 5 (very much) in 5 items and from 1 (never) to 5 (always) in the sixth. Content validity of this instrument was tested with qualitative and quantitative approaches, and investigators reported good reliability (Cella et al., 2010; Magasi et al., 2012) . Internal consistency for this study was a ¼ .91. The summary score is the mean of all items, with higher scores reflecting greater pain impact.
Psychological distress. We assessed psychological distress using the BSI, which includes 53 items that represent symptoms of nine psychological disorders: anxiety, phobic anxiety, obsessivecompulsive, depression, somatization, interpersonal sensitivity, hostility, paranoid ideation, and psychoticism (Derogatis, 1993) . The participant is asked to consider how distressed or bothered she felt during the past 7 days and then rate the symptoms from 0 (not at all) to 4 (extremely). Validity and reliability are based on testing with adult psychiatric outpatients and adult nonpatients (Derogatis, 1993) . Internal consistency for this study was a ¼ .911. We used the anxiety and depression subscales and the mean score for all items (Global Symptom Index). Higher values reflect greater psychological distress.
Severity of daily symptoms. Participants completed a symptom diary each evening, rating each symptom based on the highest severity they experienced over the past 24 hr as 0 (not present), 1 (mild), 2 (moderate), 3 (severe), or 4 (very severe). We summarized each symptom across the 14 days as percentage of days with moderate-to-very severe symptom severity. Lower-GI symptoms were abdominal pain or discomfort, pain after eating, abdominal distension, intestinal gas, bloating, constipation, diarrhea, and urgency. A composite Lower-GI Symptoms Scale was defined as the mean, over these eight symptoms, of percentage of days with moderate-to-very severe symptoms severity. A similar composite Upper-GI Symptoms Scale was calculated based on the symptoms heartburn, nausea, and stomach pain. The composite Somatic-Pain Symptoms Scale included backache, headache, and joint and muscle pain. Psychological symptoms were reported as three individual symptoms: anxiety, depression, and stress. Fatigue, a single item, was also included.
Salivary cortisol. Saliva samples were stored at À70 C. Prior to assay, samples were thawed and centrifuged at 1,500 Â g for 15 min to remove particulates. Salivary cortisol concentrations were determined using a horseradish peroxidase-linked immunoassay on 96-well microtiter plates that were coated with monoclonal antibodies to cortisol (Salimetrics, State College, PA). Expected values for women aged 18-50 years range from 0.094 to 1.545 μg/dl.
Data Analysis
Statistics were compared using Statistical Package for Social Sciences v. 15 (SPSS Inc., Chicago, IL) software. Demographics, symptoms, and pain sensitivity relative to temperature were compared using w 2 test for categorical data and independent t-test for continuous data. Distributions of continuous variable were not highly nonnormal, except for one outlier in CPM efficiency. CPM efficiency was fairly normal with that outlier removed. Data from the familiarization phase of the CPM testing protocol were used to measure pain sensitivity. Participants rated pain intensity at several different temperatures, sometimes more than once at the same temperature. For each participant, pain rating at a given temperature was measured as the average of all the ratings at that temperature, and linear regression extrapolation was used to impute missing values if a participant did not rate pain at a given temperature. Analysis of covariance, controlling for baseline between the IBS and HC group, was used to test for IBS versus HC differences in pain sensitivity, which is reported as the mean pain rating at specific temperatures from 45 to 48 C, and in CPM efficiency.
Pearson correlation was used to measure the degree of association of baseline thermal sensitivity and CPM efficiency with the composite symptom summary measures as well as with the individual symptoms. These correlation analyses were done separately for IBS and HC participants.
Results
The sample included 40 women: 20 with IBS and 20 HC. Women were on average 32 years old, and 75% were White and relatively well educated. There were no differences in demographic characteristics between the HC and IBS groups (Table 1) . Within the IBS group, 13 women identified themselves as IBS-D, 3 as IBS-C, and 4 as IBS-M. The majority of IBS participants (80%) had received a diagnosis of IBS more than 5 years prior to the study. While five women in the IBS group and three in the HC group were taking a selective serotonin reuptake inhibitor (SSRI), controlling for SSRI use did not alter any of the comparison or correlation results. Relative to the HC group, women with IBS reported significantly more GI symptoms, somatic pain symptoms (i.e., backache and muscle pain), psychological distress, and fatigue (Table 1) . Table 2 shows the participants' pain ratings at temperatures ranging from 45 to 48 C. The average pain rating was higher in the IBS group compared to the HC group, with this difference being statistically significant at 47 and 48 C. Figure 1 shows the pain intensity ratings of each participant at 45 and 48 C. There were two IBS participants who were very sensitive to pain, seen in the upper right. When stimulated with a relatively low temperature (45 C), these two participants rated pain as greater than 6. In contrast, there were nine participants who reported low pain even at 48 C, as seen in the lower left of the plot. Since 48 C was the highest temperature allowed by the protocol, this means that we conducted the CPM testing at a temperature that was lower than ideal among these nine participants in that it elicited a baseline pain rating less than the target of pain-6. Based on the determination of the pain-6 temperature, for the remainder of the CPM procedure, we tested most of the participants at 48 C (12 HC, 8 IBS) or 47 C (7 HC, 7 IBS), while testing a few at lower temperatures of 46 C (1 HC, 3 IBS), 45 C (1 IBS), or 44 C (1 IBS). Figure 2 shows that in both the IBS and HC groups, the mean pain severity rating of the thermal stimulus was higher in the unconditioned situation than it was when the conditioning stimulus (one hand immersed in cold water) was present. The mean CPM efficiency did not differ significantly between the HC and IBS groups (p ¼ .46), and both groups demonstrated a mean From the ROME III, ratings range from 1 (very mild) to 4 (very severe).
c From the Patient-Reported Outcome Measurement Information System (PROMIS-short forms), recalled over 7 days, ratings range from 1 to 5, with higher scores indicating increased pain impact or behavior. d From the Brief Symptom Inventory (BSI), symptoms recalled over 7 days, ratings range from 0 (not at all) to 4 (extremely). e From daily diary, scores were summarized to indicate percentage of days over a 14-day period in which symptoms were rated as moderate to very severe. CPM efficiency significantly greater than zero (HC: M ¼ 1.84, SD ¼ 1.12, p < .001; IBS: M ¼ 1.48, SD ¼ 1.86, p ¼ .002). In the IBS group, there was one participant who was an extreme outlier, with a CPM efficiency of À4.0, while the next lowest value was À0.7. This participant is also the highest outlier in Figure 1 . She rated the thermal pain as 6 for a temperature of 44 C in the familiarization phase but gave a pain rating of 2 at that same temperature during the unconditioned test phase (under essentially the same condition as the familiarization phase) and of 6 to this same 43 C during the conditioned stimulus (one hand in cold water). Excluding this participant does not significantly change the CPM comparison between groups (HC: M ¼ 1.84, SD ¼ 1.12; IBS: M ¼ 1.76, SD ¼ 1.38; p ¼ .85). Another nine participants (6 HC, 3 IBS) had low pain sensitivity as evidenced by reported pain levels less than 5 at a temperature of 48 C. Excluding these participants from each group did not change the conclusion that there was no significant difference in CPM efficiency between the groups (HC: M ¼ 2.21, SD ¼ 1.05; IBS:
Prior to CPM testing, salivary cortisol levels did not differ significantly between the two groups (HC: M ¼ 0.355 μg/dl, SD ¼ 0.145; IBS: M ¼ 0.357 μg/dl, SD ¼ 0.179; p ¼ .94) nor did they change within groups from before to after the CPM testing (HC: M ¼ À0.052 μg/dl, SD ¼ 0.065; IBS: M ¼ À0.030 μg/ dl, SD ¼ 0.087; p ¼ .38). In addition, there was no significant relationship between CPM efficiency and salivary cortisol level at baseline (r ¼ À.19 for HC, .03 for IBS, p > .4 for both) or change in salivary cortisol level from before to after the CPM procedure (r ¼ .19 for HC, .04 for IBS, p > .4 for both). Figure 3A and B shows the association of CPM efficiency with lower-GI and anxiety symptoms, respectively. Correlations are shown in Table 3 . The outlier in the IBS group with a very low CPM efficiency had a large influence on the correlations; removing the outlier makes the correlation with abdominal pain and lower-GI symptom scores less significant, but the correlations with anxiety, stress, and fatigue become more significant. Figure 3 highlights two interesting observations, which prompted post hoc analyses. First, 5 of the 20 IBS participants (25%) showed low CPM efficiency ( 0) as compared to 1 participant in the HC group (5%). Second, all the IBS participants with low CPM efficiency are in the right half of Figure 3A , with moderate/severe lower-GI symptoms on more than half of the days. Among those IBS participants with relatively high lower-GI symptoms, 5 of the 11 (46%) have an impaired CPM efficiency, which is significantly greater (p ¼ .013) than the 1 of the 20 in the HC group with impaired CPM efficiency.
Discussion
In the present study, we examined differences between healthy controls and women with IBS in thermal pain sensitivity and CPM. We found significant group differences in the temperature-determining phase (more women with IBS reporting pain at lower temperatures). Overall, we failed to find a significant group difference in CPM efficiency. However, in a post hoc analysis, we found that of the 11 women with lower-GI symptoms rated as moderate to severe on over half the study days, 5 demonstrated low CPM efficiency. The women with low CPM efficiency also reported more days with moderate-to-severe anxiety, stress, and fatigue. In the upper right are two IBS participants who were highly sensitive to pain, while in the lower left are nine participants with low sensitivity to pain even at 48 C. Figure 2 . Conditioned pain modulation (CPM). In both the healthy control (HC) and irritable bowel syndrome (IBS) groups, the mean pain rating for the test stimulus without conditioning is higher than the mean pain rating of the test stimulus in the presence of the conditioning stimulus (other hand submerged in cold water), demonstrating a significant CPM effect (p < .001) in both groups. Error bars represent 95% confidence intervals.
Our thermal pain sensitivity results are consistent with those of King et al. (2009) and Wong et al. (2010) , who also found that a higher thermal temperature was required to induce the targeted pain intensity range in an HC group as compared to women with IBS. However, Heymen et al. (2010) reported no baseline differences in thermal pain sensitivity in women with IBS versus HCs. Our findings related to group differences in the CPM testing effect are in the same direction but considerably weaker than those of Heymen et al., Wong et al., and King et al., all of whom found reduced CPM efficiency among subjects with IBS compared with HCs. Although the study samples are similar among these studies, we did not exclude women taking SSRIs, as did the other researchers. However, when we controlled for SSRI use in our analysis, the findings did not change. Heymen et al. and King et al. did not exclude women who had both IBS and other chronic pain conditions, while Wong et al. did. All the participants with IBS in the Wong et al. study had IBS-D, while the other two studies as well as the present study included participants with IBS-D, IBS-C, and IBS-M. With regard to other chronic pain conditions, our study protocol specifically excluded women with moderate-to-severe comorbid pain (e.g., fibromyalgia) or psychiatric conditions. This exclusion was important since Chang et al. (2009) , in measuring both visceral and somatic sensitivity, found that IBS patients with comorbid fibromyalgia showed an enhanced sensitivity to unpleasant somatic stimuli. Interestingly in that study, participants with only IBS showed a blunted response to somatic stimuli. In the current study, we noted that although women with IBS did report in the daily diary more days with backaches and muscle pain, there was no significant correlation of somatic symptoms with CPM efficiency. It is possible that recruitment site could have accounted for some of the differences across studies. In Heymen et al.'s study (2010) , women were recruited from a functional GI disorder data registry as well as the community. King et al. (2009) recruited from clinics. It is not clear how Wong et al. (2010) recruited participants. In the present study, we used a community recruitment approach; thus, women with IBS may represent a less symptomatic group relative to the other studies.
Our results provide the first evidence that women with IBS who do exhibit a reduced CPM efficiency are more likely to report more days with moderate-to-severe lower-GI symptoms, anxiety, and fatigue. The decreased ability to inhibit sensory input (reduced CPM efficiency), seen in approximately one fourth of our IBS group, may explain why some IBS patients respond to ''normal'' bowel sensations (e.g., intestinal gas) as painful. Given the potential plasticity of CPM efficiency, constant or repeated stimulation (e.g., stress) may produce changes that result in a decreased ability to dampen peripheral input (Ossipov, Dussor, & Porreca, 2010) .
It is interesting that when we removed one outlier from the analysis, we observed a significant negative relationship of daily stress with CPM efficiency. How the perception of daily and chronic or repeated stress physiologically influences CPM efficiency is not clear. Descending pain modulatory systems are complex. CPM efficiency stems from a spino-bulbar-spinal loop that receives input from higher centers. Authors have suggested that changes in the hypothalamus contribute to the hypoactivity of the pain inhibitory system (Trimble, Johnson, Foster, & Greenwood-van Meerveld, 2007) . Several studies have demonstrated that some patients with IBS show evidence of a dysregulated HPA axis as reflected in high or low cortisol levels under basal and stress conditions (Chang et al., 2009; Heitkemper et al., 2012) . Using salivary cortisol levels as a peripheral marker of the HPA axis, we failed to find baseline group differences in response to the CPM testing. All testing procedures were conducted within the same time period in the day to control for circadian variation. Our finding that the CPM testing did not elicit a physiologic stress response is consistent with Campbell et al.'s (2008) study in which they observed no difference in cardiovascular reactivity variables including heart rate and blood pressure during and following CPM testing. Additional studies are warranted to elucidate the roles of the sympathetic nervous system and the HPA axis in pain modulation in IBS.
The findings of the current study should be interpreted with caution. First, the sample size is relatively small, and approximately 50% of the IBS group had lower-GI symptoms that were moderate to severe on less than 50% of study days. Second, almost half of the HC participants exhibited reduced pain sensitivity at the study's upper limit of 48 C (thermode). Since the aim of the initial phase of the CPM testing was to identify the temperature at which pain intensity was rated at 6, the temperature for conducting the CPM testing should ideally have been greater than 48 C. Our inability to increase the testing thermode temperature to greater than 48 C due to protocol may have contributed to the large number of HC participants whose pain level did not reach a rating of moderate (6) or higher.
Our finding in the present study that the impaired CPM efficiency we observed in a subset of women with IBS is associated with more severe lower-GI symptoms, higher anxiety, and greater fatigue adds to the growing evidence supporting the importance of pain-related mechanisms in a substantial subset of women with IBS. Understanding the roles of peripheral and central mechanisms in a chronic condition such as IBS is crucial to the development and testing of effective pharmacologic and nonpharmacologic (e.g., cognitive-behavioral therapy) therapies.
